Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Adv Exp Med Biol. 2024;1448:59-71. doi: 10.1007/978-3-031-59815-9_6.
In the past two decades, there has been a great deal of work aimed to devise diagnostic guidelines, classification criteria, and diagnostic scores for cytokine storm syndromes (CSSs). The most notable effort has been the large-scale multinational study that led to the development of the 2016 classification criteria for macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (JIA). Future studies should scrutinize the validity of the proposed criteria, particularly in systemic JIA patients treated with biologics, in children with subtle or incomplete forms of MAS, and in patients with MAS complicating other rheumatologic disorders. More generic CSS criteria are also available but often lack sensitivity and specificity in a wide variety of patient populations and CSSs of different etiologies. The coronavirus disease 2019 (COVID-19)-related lung disease led to an evolution of the concept of a "cytokine storm." Emerging and unsolved challenges in the diagnosis of the different forms of CSSs highlight the need for diagnostic tools and well-established classification criteria to enable timely recognition and correct classification of patients.
在过去的二十年中,已经有大量的工作旨在制定细胞因子风暴综合征 (CSSs) 的诊断指南、分类标准和诊断评分。最引人注目的努力是一项大规模的多国研究,该研究导致了 2016 年系统性幼年特发性关节炎 (JIA) 合并巨噬细胞活化综合征 (MAS) 的分类标准的制定。未来的研究应仔细审查所提出标准的有效性,特别是在接受生物制剂治疗的系统性 JIA 患者、具有轻微或不完整 MAS 形式的儿童以及 MAS 合并其他风湿性疾病的患者中。也有更通用的 CSS 标准,但在各种不同病因的患者人群和 CSS 中往往缺乏敏感性和特异性。与 2019 年冠状病毒病 (COVID-19) 相关的肺部疾病导致了对“细胞因子风暴”概念的演变。不同形式 CSSs 的诊断中出现的新的和未解决的挑战突出表明需要诊断工具和既定的分类标准,以便及时识别和正确分类患者。